Avidity Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.
Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.
We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.
BeAVID
133 articles about Avidity Biosciences
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 23, 2023
10/23/2023
Avidity Biosciences, Inc. announced that on October 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,200 shares of its common stock and 48,100 restricted stock units to twelve new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1
10/7/2023
Avidity Biosciences, Inc. announced new positive AOC 1001 data demonstrating improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1.
-
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
9/26/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina.
-
Avidity Biosciences to Participate in Upcoming Investor Conferences - September 25, 2023
9/25/2023
Avidity Biosciences, Inc. today announced that Avidity management will be participating at the following upcoming conferences.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2023
9/21/2023
Avidity Biosciences, Inc. announced that on September 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,300 shares of its common stock and 45,150 restricted stock units to nine new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
9/7/2023
Avidity Biosciences, Inc. announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases.
-
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
8/31/2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference.
-
Avidity Biosciences to Participate in Upcoming September 2023 Investor Conferences
8/30/2023
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following upcoming conferences.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 21, 2023
8/21/2023
Avidity Biosciences, Inc. announced that on August 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 42,100 shares of its common stock and 21,050 restricted stock units to thirteen new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
8/15/2023
Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1044, the company's investigational therapy in development for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44).
-
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
8/8/2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the second quarter ended June 30, 2023.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 21, 2023
7/21/2023
Avidity Biosciences, Inc. announced that on July 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 33,150 shares of its common stock and 16,575 restricted stock units to eleven new non-executive employees under the Avidity Biosciences, Inc.
-
Avidity Biosciences to Participate in Upcoming Investor Conference
6/29/2023
Avidity Biosciences, Inc. today announced that Avidity management will be participating at the following conference.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 21, 2023
6/21/2023
Avidity Biosciences, Inc. announced that on June 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 23,650 shares of its common stock and 11,825 restricted stock units to four new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress
6/8/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the company will be presenting two oral presentations and two poster presentations at the 30th Annual FSHD Society International Research Congress, being held June 15-16, 2023, in Milan, Italy.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 22, 2023
5/22/2023
Avidity Biosciences, Inc. announced that on May 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,900 shares of its common stock and 18,450 restricted stock units to eight new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1
5/17/2023
Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has eased the partial clinical hold on AOC 1001, allowing Avidity to double the number of participants in the MARINA Open-Label Extension (MARINA-OLE™) study receiving 4 mg/kg of AOC 1001.
-
Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
5/9/2023
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, reported financial results for the first quarter ended March 31, 2023 and highlighted recent corporate progress.
-
Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1
4/27/2023
Avidity Biosciences, Inc. announced positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 demonstrating functional improvement, DMPK reduction, splicing improvements and a favorable safety and tolerability profile.
-
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
4/24/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44).